Ontario’s New Fetal Blood Type Screening Is Bringing Precision Medicine to Pregnancy

There is a quiet but serious risk that has existed in pregnancy care for decades. It involves blood type, a developing baby, and a mismatch between the two that, if undetected, can cause fetal anemia, brain damage, stillbirth, or death in the newborn period. The condition is called hemolytic disease of the fetus and newborn, and until today, managing it in Ontario required giving a human blood product to every pregnant person at risk, whether they needed it or not.

That changes now. And the change is more significant than most people realize.

What Ontario Just Launched

As of today, BORN Ontario and Prenatal Screening Ontario have launched two new publicly funded prenatal screening tests that determine a fetus’s blood type using a simple blood draw from the pregnant person. No needles into the uterus. No risk to the baby. Just a blood sample, analyzed for fetal DNA circulating in the mother’s bloodstream, that can tell clinicians exactly what blood type the fetus carries.

The two new tests are fetal RHD screening, for RhD-negative pregnant individuals, to determine whether their fetus is actually RhD-positive and therefore at risk of triggering an immune reaction, and alloimmunized fetal blood group genotyping, for pregnant individuals who already have certain antibodies, to guide how closely the pregnancy needs to be monitored.

Both tests are part of Ontario’s $9.8 million investment in prenatal screening services and are available through Prenatal Screening Ontario and the laboratory infrastructure of Sinai Health and Canadian Blood Services.

The Problem These Tests Are Solving

To understand why this matters, it helps to understand the biology.

Blood type is determined by antigens on the surface of red blood cells. The RhD antigen, part of the Rhesus system, is either present (RhD-positive) or absent (RhD-negative). Approximately 15% of people of European descent are RhD-negative. When an RhD-negative person carries an RhD-positive fetus, a small amount of fetal blood can cross the placenta into the mother’s bloodstream. The mother’s immune system, encountering this foreign antigen for the first time, can develop antibodies against it. In a subsequent pregnancy with another RhD-positive fetus, those antibodies can cross back through the placenta and attack the baby’s red blood cells, causing hemolytic disease of the fetus and newborn.

Before the introduction of RhD immune globulin (RhIG) prophylaxis in the 1960s, HDFN was a devastating condition. Historically, up to 14% of affected pregnancies resulted in stillbirth, and up to 50% of live births were complicated by fetal anemia, brain damage from jaundice, or neonatal death, according to the Journal of Obstetrics and Gynaecology Canada. RhIG, a human blood product derived from plasma donors, transformed that picture. Given at 28 weeks gestation and after delivery, it prevents the mother’s immune system from developing those antibodies in the first place.

But here is the problem. RhIG is given routinely to all RhD-negative pregnant individuals, regardless of whether the fetus is actually RhD-positive. Approximately 40% of RhD-negative pregnant individuals are carrying an RhD-negative fetus, which means they face no risk of alloimmunization at all. They have been receiving a human blood product they never needed.

Why That Matters: RhIG Is Not Unlimited

This is not merely a matter of an unnecessary needle. RhIG is a plasma-derived product, meaning it comes from human blood donors. It is in limited global supply, and like all blood products, it carries a small but real risk profile. Giving it unnecessarily is not only wasteful; it represents a stewardship problem for a resource that genuinely cannot be manufactured from scratch.

Canadian Blood Services has noted that some pregnant individuals also have blood typing variability that can make serological testing ambiguous, and that identifying fetal blood type directly from maternal blood provides a more definitive and clinically useful answer than relying on the mother’s serology alone. A Canadian study of prenatal patients found that 0.4% of women identified as RhD-negative by standard serology had serological variability, with 61% of those actually carrying a weak D variant that meant they were effectively RhD-positive and did not require RhIG at all.

The new fetal blood type screening tests resolve that ambiguity directly, at the source.

The Technology Behind It

The tests use cell-free fetal DNA, fragments of the baby’s genetic material that circulate in the pregnant person’s bloodstream from early in pregnancy. This is the same technology that underpins non-invasive prenatal testing for chromosomal conditions like Down syndrome, which Ontario has funded since 2014.

Analyzing cell-free fetal DNA for the RHD gene allows laboratories to determine with high accuracy whether the fetus is RhD-positive or RhD-negative, using only a maternal blood draw. For the alloimmunized fetal blood group genotyping test, the same approach is extended to other blood group antigens relevant to pregnant individuals who have already developed certain antibodies.

The clinical accuracy of this approach has been validated internationally and is now incorporated into the standard of care in several European countries. A 2025 review in the Journal of Obstetrics and Gynaecology Canada confirmed that non-invasive fetal RHD genotyping supports targeted RhIG prophylaxis and reduces unnecessary blood product use in RhD-negative pregnancies.

What This Means for Pregnant Ontarians

The practical effect of this change is a shift from what the announcement calls a one-size-fits-all approach to genuinely personalized pregnancy care.

For the roughly 40% of RhD-negative pregnant individuals whose fetus is RhD-negative, the test result means they can be confidently spared RhIG injections they never needed. For those whose fetus is RhD-positive, it confirms the treatment is both necessary and appropriately targeted. For individuals who are already alloimmunized and carrying antibodies, the genotyping test guides how intensively the pregnancy should be monitored, without subjecting every alloimmunized individual to the same level of intervention regardless of actual fetal risk.

The tests are publicly funded, meaning eligible pregnant individuals in Ontario access them through the existing prenatal screening pathway at no cost.

The Bigger Picture

This is a story about precision medicine arriving in one of the most important clinical contexts imaginable: pregnancy. The idea that a blood draw can now tell a clinician the blood type of an unborn baby, and use that information to make treatment decisions that are tailored rather than precautionary, represents a meaningful advance in how prenatal care is delivered.

BORN Ontario, the province’s perinatal data and registry network, will support the rollout and ongoing data collection, ensuring the program’s effectiveness can be measured and refined over time.

“This new screening program represents a significant advancement in precision prenatal care,” said Dr. Barbra de Vrijer, a Maternal-Fetal Medicine Specialist involved in the launch. “By better identifying which pregnancies require intervention and monitoring, we can tailor care more effectively and improve outcomes for both pregnant individuals and babies.”

For families expecting a child in Ontario, that is not a small thing. It is the difference between a precautionary system that treats everyone the same and a care model that finally knows who actually needs what.

Ontario is the first province in Canada to publicly fund and implement fetal blood type screening at a population level. Research from Alberta previously modeled the cost-effectiveness of exactly this approach, finding that targeted RhIG prophylaxis guided by fetal RhD genotyping would save thousands of unnecessary doses annually in that province alone. Whether Alberta and other provinces move to adopt similar programs remains to be seen. We will be watching for announcements from other provincial health systems and will update our coverage as this important screening rolls out across Canada.

Subscribe to The Health Insider newsletter where you’ll find many more insights – delivered straight to your inbox.

~ Read more from The Health Insider ~

• 
  Inked and Informed: What New Research Reveals About Tattoos, Lymphoma, and Health Risks
  New research links tattoos to lymphoma risks. Explore the health science, Canadian stats, infection risks, and skin diagnostic challenges.
• 
  Taking Antibiotics? Your Sweet Tooth Might Be Making Things Worse
  New research in Nature shows eating sugary foods while taking antibiotics could amplify gut microbiome damage. Learn what the study revealed.
• 
  Ottawa Indefinitely Extends the MAID Exclusion for Mental Illness. Here Is What Changes.
  Ottawa has indefinitely extended the exclusion of mental illness as a sole condition for MAID. Learn what changes and what the data shows.
• 
  Magnesium vs. Melatonin for Sleep: What Science Says
  Compare magnesium and melatonin for sleep. Discover Canadian stats, expert evidence, optimal dosages, risks, and which supplement fits you.
• 
  Women’s Heart Attacks: The Fatal Gap in Care You Need To Know About
  Women experience heart attacks differently than men and are often misdiagnosed. Know the subtle warning signs and how to insist on sex-specific testing.
• 
  Ontario Pays Private Clinics More. Wait Times Keep Rising.
  A CCPA report shows Ontario’s for-profit health clinics cost taxpayers more, increase wait times, and lead to unlawful patient fees.

The information provided on TheHealthInsider.ca is for educational purposes only and does not substitute for professional medical advice. TheHealthInsider.ca advises consulting a medical professional or healthcare provider when seeking medical advice, diagnoses, or treatment. To read about our editorial review process click here.